Drugs / rDEN3∆30
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02684383 | ? → Jul 2016 | dengue disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rDEN3∆30 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02684383 ↗ |
| Modality | Vaccine | “live attenuated monovalent dengue virus vaccine (rDEN3Δ30)” NCT02684383 ↗ |
| Route | Subcutaneous | “administered by subcutaneous injection in the deltoid region of the upper arm” NCT02684383 ↗ |